1. Medtech Insight
  2. >>Policy & Regulation

Experts Tell US Congress: Labs Must Improve Capacity, Carry Out 3.5 Million COVID-19 Tests Weekly

 
• By Sue Darcey

Public health experts told a House Appropriations Subcommittee on 6 May that the federal government must provide states enough point-of-care COVID-19 rapid test supplies and dollars to improve public laboratory capacity to conduct millions of tests each week to subdue the coronavirus.

Test tubes with blood sample on coronavirus. Money background. How much is cost analysis on Covid-19. S

Two public health experts told members of a key House Appropriations Committee subpanel on 6 May the US should be conducting about 3.5 million COVID-19 rapid, point-of-care tests per week to control the disease.

Barriers to achieving that testing number include the federal government providing the states with sufficient testing supplies like nasal swabs, assay medium and personal protective equipment, former Centers for Disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.